Cosmo Pharmaceuticals
Cosmo Pharmaceuticals specializes in developing, manufacturing, and distributing pharmaceutical products globally, focusing on gastrointestinal diseases and dermatology. Its portfolio includes Lialda/Mezavant for ulcerative colitis, Zacol NMX for colon disorders, and Eleview for submucosal injections during endoscopic procedures. The company's pipeline comprises innovative treatments for inflammatory bowel diseases like ulcerative colitis and Crohn's disease, as well as products for travellers' diarrhoea, opioid-induced constipation, acne, alopecia, and hirsutism.
Top Stages
2 past transactions
Cristoforo Colombo Real Estate
Acquisition in 2012
Cristoforo Colombo Real Estate is a provider of real estate services.
BioXell
Acquisition in 2009
BioXell was founded in 2002 as a spinout of Roche Milano Ricerche, a leading biomedical research institute created ten years earlier that focused on chronic inflammatory disease and autoimmunity.
The idea to create BioXell originated with Francesco Sinigaglia, founder and director of the Milan-based research institute, following a scientific career path that took him to the University College in London, the Basel Institute of Immunology and the Hoffmann-La Roche research units in Basel. Dr. Sinigaglia, former CEO, approached Roche with his challenging project and a year later BioXell was spun off, with $22m invested by MPM Capital, Index Ventures and Life Science Partners.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.